Reyataz

 

Topic mentions per year

Topic mentions per year

2003-2014
0246820032014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Current treatments Twenty-six active pharmaceutical ingredients (APIs) in five major drug classes, targeting various stages of… (More)
  • figure 1
  • table 1
Is this relevant?
2012
2012
  • International Journal of Pharmaceutical Medicine
  • 2012
 
Is this relevant?
2011
2011
Atazanavir (Reyataz; ATV) is a well-tolerated protease inhibitor (PI) that is indicated as a once-daily treatment for HIV… (More)
  • table 1
  • table 3
  • table 2
  • figure 1
  • figure 2
Is this relevant?
2007
2007
BACKGROUND HIV/AIDS incidence and mortality rates have decreased in the U.S. since 1996. Accompanying the longer life spans of… (More)
  • table 1
  • table 2
  • figure 2
  • table 3
  • table 4
Is this relevant?
2004
2004
  • AIDS treatment news
  • 2004
The combination has been found to reduce blood levels of the antiretroviral to about a quarter of what they should be. 
Is this relevant?
2004
2004
  • AIDS treatment news
  • 2004
The FDA published new information on drug interactions that patients taking Reyataz should know. 
Is this relevant?
2003
2003
  • Project Inform perspective
  • 2003
Atazanavir (Reyataz) is a protease inhibitor that received FDA approval in June 2003. Other approved drugs in this class include… (More)
Is this relevant?
2003
2003
  • AIDS alert
  • 2003
Reyataz, protease inhibitor, is to be used in combination with other antiretroviral agents for the treatment of patients with HIV… (More)
Is this relevant?
2003
2003
In June 2003, atazanavir sulphate (Reyataz; Bristol-Myers Squibb) — the first once-daily HIV-1 protease inhibitor — was approved… (More)
  • figure 1
  • table 1
  • figure 2
Is this relevant?
2003
2003
  • Paul Pham
  • The Hopkins HIV report : a bimonthly newsletter…
  • 2003
 
Is this relevant?